{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019851","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.537942+00:00","generated_at":"2026-06-25T17:58:43.343727+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eledon Pharma Q1 net loss $9.9M; ALS topline data expected June 2022","bullets":["Net loss $9.9M ($0.69/diluted share) vs $8.5M ($0.57) in Q1 2021.","Cash $76.7M as of March 31, 2022, down from $84.8M; runway into 2024.","Phase 2a ALS trial fully enrolled; topline data anticipated in June 2022.","First patient dosed in Phase 2a IgA Nephropathy trial; initial data late 2022.","Non-human primate study of tegoprubart monotherapy in kidney allograft rejection completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019851","json":"https://secwatch.observer/filing/0001564590-22-019851.json","markdown":"https://secwatch.observer/filing/0001564590-22-019851.md","text":"https://secwatch.observer/filing/0001564590-22-019851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000156459022019851/0001564590-22-019851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000156459022019851/eldn-8k_20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:58:43.343727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}